Royalty Pharma (RPRX) Debt Ratio (2019 - 2026)

Royalty Pharma (RPRX) posted Debt Ratio of 0.47 for Q1 2026, down 0.92% sequentially from 0.48 in Q4 2025, and up 8.91% YoY from 0.43 in Q1 2025.

Royalty Pharma (RPRX) Debt Ratio (2019 - 2026) Analysis & Trends

Royalty Pharma has reported Debt Ratio for 8 years, with the latest figure at 0.47 in Q1 2026.

Quarterly Debt Ratio rose 8.91% year-over-year to 0.47 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.47 (up 8.91% YoY) and the FY2025 annual result came in at 0.48, up 0.65% from the prior year.
Debt Ratio declined to 0.47 in Q1 2026 per RPRX's latest filing, from 0.48 in the prior quarter.
Over five years, Debt Ratio peaked at 0.48 in Q1 2023 and troughed at 0.37 in Q4 2023.
A 5-year average of 0.43 and a median of 0.43 in 2024 frame the typical range for Debt Ratio.
The widest YoY moves for Debt Ratio: up 26.16% in 2024, down 19.97% in 2024.
Over 5 years, Debt Ratio stood at 0.42 in 2022, then slipped by 11.51% to 0.37 in 2023, then rose by 26.16% to 0.47 in 2024, then rose by 0.65% to 0.48 in 2025, then retreated by 0.92% to 0.47 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.47, 0.48, and 0.46 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn	-

Download Data